In human myeloma cell lines (HMCLs), a synergism between of compounds individually inhibiting Bcl-2 and Mcl-1 has been confirmed, and the combination of these drugs overcomes Mcl-1 resistance in MM (118, 119). This evidence concerns the gene MCL1 and plasma cell myeloma.